Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual CareLIFEMAP Research Group Meeting Objective: To review recent AI-CVD and Agatston-2.0 research progress, discuss the latest LDCT Mega Trial / LIFEMAP study design, evaluate key unresolved protocol questions, introduce LUNGevity as a potential nonprofit administrative and advocacy partner, and begin discussion of funding sources and fundraising plans. 1. Opening Remarks Dr. Mo

Campaign contrasts coronary plaque-centric AI-CCTA marketing with AI-CVD's CAC-based, whole-patient primary prevention approach: one lower-cost, lower-radiation, non-contrast CT scan, 10+ actionable reports, and broader cardiovascular and cardiometabolic risk phenotyping. SAN DIEGO, July 6, 2026 - HeartLung Corporation (HeartLung.AI), a medical AI company transforming CT imaging into preventive care intelligence, today announced the launch of its "Why Pay More and Get Less?"

AI-derived left atrial volume and chamber ratios from CAC scans predicted long-term AF and stroke in MESA and Framingham. HOUSTON, June 18, 2026 - HeartLung.AI today announced that its research article, "AI-Derived LA Volume Index, LA/RA and LA/LV Volume Ratios From Coronary Artery Calcium Scans Predict Long-Term Atrial Fibrillation and Stroke," was featured on the June 2026 episode of the Stroke Alert Podcast, the podcast of Stroke, a journal of the American Heart Associatio

New peer-reviewed study introduces Agatston-2.0, led by Morteza Naghavi, MD, with Arthur S. Agatston, MD, the originator of the original Agatston score, and leading cardiovascular imaging and prevention experts. HOUSTON, TX, June 2026 — HeartLung Corporation today announced the publication of a landmark peer-reviewed study introducing Agatston-2.0, a next-generation artificial intelligence-based coronary artery calcium scoring method designed to modernize one of the most infl

HOUSTON, TX, May 18, 2026 - HeartLung Corporation announced the publication of a new study in the American Journal of Preventive Cardiology titled “Comparing Incidence of Heart Failure in Individuals with Enlarged Cardiac Chambers versus Diabetes.” The study demonstrates that HeartLung’s AI-CVD AutoChamber module can opportunistically identify left atrial enlargement, left ventricular enlargement, and increased left ventricular mass from routine coronary artery calcium scans,

Accepted studies showcase HeartLung.AI’s leadership in AI-CVD, opportunistic CT screening, Agatston 2.0, chamber volumetry, and preventive cardiology. HOUSTON, Texas, 05/11/2026 – HeartLung.AI today announced that 10 scientific abstracts have been accepted for presentation at ESC Congress 2026, the annual meeting of the European Society of Cardiology. The accepted studies showcase HeartLung.AI’s growing leadership in AI–enabled cardiovascular imaging and preventive cardiology

New intellectual property milestones strengthen HeartLung’s leadership in AI–enabled preventive CT imaging and coronary inflammation assessment HOUSTON, TX, UNITED STATES, May 3, 2026 /EINPresswire.com/ -- HeartLung Corporation, a medical technology company advancing AI–enabled, CT–based opportunistic screening and early disease detection, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,620,494, titled “Predicting adverse healt

CMS Code G0680 opens doors to AI-enabled opportunistic detection of patients with silent coronary artery disease who are unaware of their risk of a future heart attack. HOUSTON, April 7, 2026 -- HeartLung AI today welcomed CMS’s establishment of HCPCS code G0680 in the April 2026 Hospital Outpatient Prospective Payment System update, effective April 1, 2026, for algorithmic analysis of coronary artery calcium (CAC) and/or aortic valve calcification from chest CT with report.

Houston, TX – [March 18, 2026] – HeartLung Technologies today announced strong support for the newly released 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia, which introduces a major paradigm shift in cardiovascular prevention: the formal recognition of opportunistic detection of coronary artery calcium (CAC) on routine noncardiac CT scans, including the use of validated artificial intelligence algorithms. For the first time, leading cardiovascular soci

AutoChamber™ and AutoBMD™ AI solutions will soon be available on Precision Imaging Network, with AI-CVD® planned next. HOUSTON, TX, UNITED STATES, February 3, 2026 -- HeartLung.AI , an AI-enabled company focused on early detection and prevention of heart disease, lung cancer, osteoporosis, emphysema and fatty liver disease using widely available CT scans, announced that its AutoChamber™ and AutoBMD™ AI services will be available through Precision Imaging Network, part of Mic

New Orleans, LA — HeartLung Corporation announced today that CommonSpirit Memorial Hospital-Breathe Easy Mobile Lung Screening , developed and led by HeartLung Scientific Advisor Dr. Robert Headrick, MD, MBA , is being featured this week at the Society of Thoracic Surgeons (STS) Annual Meeting in New Orleans. Breathe Easy was created to address a persistent challenge in lung cancer prevention: many high-risk individuals do not complete recommended screening due to real-wor

Award-winning presentation recognizes AI-CVD-HF heart failure prediction model leveraging coronary artery calcium (CAC) scans Hong Kong — 01/27/2026 — HeartLung AI announced today that Seyed Reza Mirjalili, MD , a fellow AI-CVD investigator , has been named the Rapid-Fire Winner at SCCT Global 2026 in Hong Kong , recognizing his outstanding scientific presentation and contribution to the field of preventive cardiovascular CT. Dr. Mirjalili received the award for his rapid-

FDA-cleared AI-CVD® extracts preventive insights from routine CT—identifying hidden cardiovascular, metabolic, and skeletal risk in ~40M scans/year Houston, TX – January 12th, 2026 — HeartLung Corporation today announced U.S. Food and Drug Administration (FDA) clearance of AI-CVD® , its flagship AI-powered quantitative imaging platform, under 510(k) K252029 , marking a major inflection point in preventive medicine and opportunistic screening. With this clearance, AI-CVD® be

Houston, TX — HeartLung AI today recognized its scientific advisors, including Robert A. Kloner, MD, PhD; Arthur Agatston, MD, FACC; Claudia Henschke, MD, PhD; and David Yankelevitz, MD, as internationally recognized pioneers whose work has helped shape modern cardiovascular prevention and lung cancer screening. As part of this leadership, HeartLung AI is highlighting a recent publication by Dr. Robert A. Kloner and colleague featured in a companion volume to Braunwald’s Hea

Houston, TX — December 2025 — HeartLung announced today the publication of a landmark Editorial Viewpoint in JACC: Cardiovascular Imaging , led by Morteza Naghavi, MD , founder of HeartLung, urging the Centers for Medicare & Medicaid Services (CMS) to recognize coronary artery calcium (CAC) imaging as a diagnostic test and initiate national coverage. The Viewpoint, “Coronary Artery Calcium (CAC) Imaging as a Diagnostic Test: Insurance Coverage Implications,” represents the

Agatston 2.0 and AI-CVD unveiled in a new SCCT-hosted webcast, showcasing the next generation of calcium scoring and cardiometabolic imaging. HOUSTON, TX, UNITED STATES, November 20, 2025 / EINPresswire.com / -- The Society of Cardiovascular Computed Tomography (SCCT) and HeartLung.AI today announced the release of a new sponsored webcast, “Agatston 2.0: The next generation of calcium scoring in the era of AI-CAC and AI-CVD.” The free webcast, sponsored by HeartLung.AI , br

Hosted by Society of Cardiovascular Tomography (SCCT) Agatston 2.0: The next generation of calcium scoring in the era of AI-CAC and AI-CVD Full Video View Part 1 View Part 2 Webcast Summary Thirty years ago, the Agatston Score pioneered CT-based coronary atherosclerosis imaging. Since then, extensive evidence has established CAC as the strongest predictor of CHD events. However, two limitations have constrained its clinical utility: “Power of Zero” exceptions: Alth

New Orleans, LA — October 21, 2025 — HeartLung Technologies today announced a record-setting presence at the upcoming American Heart Association (AHA) Scientific Sessions 2025, with nine peer-reviewed studies accepted for presentation—spotlighting breakthroughs from the company’s AI-CVD™ platform, including AI-CAC™ and novel CT-derived cardiometabolic imaging biomarkers. The work spans prediction of coronary “soft plaques”, heart failure, atrial fibrillation, COPD, non-zero

HOUSTON, TX — The American Heart Association (AHA) has released an official Scientific Statement in Circulation recognizing AI-enabled opportunistic detection of coronary artery calcium (CAC) on routine chest CT scans as an emerging cornerstone for cardiovascular disease prevention . The statement, titled “Opportunistic Detection of Coronary Artery Calcium on Noncardiac Chest Computed Tomography: An Emerging Tool for Cardiovascular Disease Prevention,” highlights the tr

October 07, 2025 I Louisville, KY – 3DR Labs, the nation’s largest and most trusted provider of 3D medical image post-processing, today...